Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization diseases.
We are pursuing the development of therapeutics to address the underlying causes of these debilitating, rare diseases through our in-depth understanding of the biological pathways involved in mineralization. We’re leveraging the insights of the key role that the genes ENPP1 and ABCC6 play in the critical mineralization pathway. An abnormal mineralization occurs when there is a deficiency in ENPP1 and ABCC6. Our focus is developing a novel therapy to treat the rare diseases that are a consequence of ENPP1 and ABCC6 deficiencies.
Henric Bjarke joined Inozyme Pharma in July 2017 and has served as our senior vice president and chief operating officer since then. Prior to joining our company, Mr. Bjarke served as senior vice president, chief commercial officer of IVERIC from September 2015 to April 2017.
Mr. Bjarke served as vice president, global metabolic disorders franchise of Alexion from November 2012 to August 2015 and as vice president, North America commercial operations of Alexion from September 2010 to November 2012. Prior to joining Alexion, Mr. Bjarke served in various commercial roles at Watson Pharmaceuticals, Eyetech Pharmaceuticals, Inc. and Pharmacia Corporation. Mr. Bjarke received a B.A. Sc. in business administration and economics from Uppsala University in Sweden.
Read More +Read Less -Axel Bolte is our president and chief executive officer and is a member of our board of directors since September 2015, when he co-founded our company. Since March 2017, Mr. Bolte also has served as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company.
Mr. Bolte served as a venture partner at HBM Partners AG, a provider of investment advisor services in the life sciences industry, from February 2017 to September 2019 and as an investment advisor to HBM Partners AG from March 2003 to January 2017. Mr. Bolte currently serves on the board of directors of IVERIC bio, Inc. (formerly known as Ophthotech Corporation), or IVERIC, and previously served on the board of directors of Allena Pharmaceuticals, Inc., Nabriva Therapeutics plc and PTC Therapeutics, Inc., all of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland
Read More +Read Less -Gayle Gironda joined Inozyme in July 2021 and serves as our senior vice president of human resources. She has more than 20 years of experience in organizational design, talent recruitment, performance culture, planning and leadership development.
Ms. Gironda offers a deep knowledge of life sciences, stemming from her work with large multinational pharmaceutical organizations as well as small biotech companies. She previously served as vice president, human resources, global hematology and global market access at Bristol Myers Squibb (BMS), playing a key role integrating the Hematology Business Unit as part of the company’s acquisition of Celgene. Additionally, she supported the Global Market Access, Pricing and Health Economics and Outcomes Research (HEOR) teams through post-acquisition strategy, organizational design and talent alignment. Before joining Celgene in 2018 as vice president, human resources, global franchises, Ms. Gironda was executive director, HR, commercial operations at Alexion Pharmaceuticals. Her previous experience also includes leadership roles in human resources and operations for small-to-mid-sized companies such as Watson/Actavis, Jerini Ophthalmic, Inc. and Eyetech Pharmaceuticals. Ms. Gironda received a B.A. in liberal studies from SUNY Purchase.
Read More +Read Less -Yves Sabbagh, Ph.D., is our senior vice president and chief scientific officer, joining Inozyme in October 2020. Dr. Sabbagh brings to Inozyme more than 20 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates.
Prior to joining Inozyme, Dr. Sabbagh served as the head of rare renal and musculoskeletal diseases research at Sanofi. Prior to that executive role, he held scientific roles of increasing responsibility at Sanofi and Genzyme Corporation spanning endocrine, renal and rare bone diseases including driving the strategy for bone indications. Prior to his corporate experience, he was an instructor at the Harvard Medical School in the Endocrine unit. Dr. Sabbagh has co-authored more than 30 peer-reviewed publications and book chapters and is a member of several scientific societies. Dr. Sabbagh received a B.Sc. in biochemistry from McGill University, an MSc in microbiology from Université Laval and a Ph.D. in biology from McGill University.
Read More +Read Less -David Thompson rejoined our leadership team in July 2021 as chief development officer, after previously serving as our senior vice president and chief scientific officer from 2018 to 2020. In his former role, Dr. Thompson was responsible for scientific research as the company built its proprietary pipeline of investigational therapies, beginning with INZ-701.
He has more than 30 years of experience designing and leading research and development programs focused on bone disorders and phosphate regulation. Prior to joining Inozyme Pharma, Dr. Thompson was a founder and president of Azure Biotech, where he was responsible for the development of a novel formulation of lasofoxifene, a non-steroidal selective estrogen receptor modulator used for the prevention and treatment of osteoporosis and the treatment of vaginal atrophy. Previously, Dr. Thompson held executive positions in clinical research and drug development in multiple biopharma companies, including Alexion Pharmaceuticals, where he led the clinical development of asfotase alfa for the treatment of hypophosphatasia; and Pfizer, where he oversaw the osteoporosis research and frailty discovery groups. While at Merck Research Labs, he conducted preclinical work and participated in the early clinical development of alendronate for the treatment of osteoporosis. Dr. Thompson received his M.A. from the University of Montana and both his M.S. and Ph.D. from the University of Connecticut.
Read More +Read Less -Sanjay Subramanian joined Inozyme as Chief Financial Officer in March 2022. He brings to Inozyme over 20 years of corporate finance, capital markets, and business development expertise. Prior to joining Inozyme, Mr. Subramanian served as CFO and head of corporate development at Ocugen, Inc., where he led the company’s finance, investor relations, and business development functions.
At Ocugen, Mr. Subramanian was instrumental in improving its capital structure, raising over $200 million, and leading transformative collaboration. Prior to Ocugen, he held roles of increasing responsibility at Aralez Pharmaceuticals, most recently as CFO, and played a key role in the Aralez formative transaction and its listing on Nasdaq and TSX. Mr. Subramanian also previously held positions of increasing responsibility at Bausch Health Companies, including playing a key role in the acquisition, financing, and post-merger integration of Bausch & Lomb. Before Bausch Health, Mr. Subramanian was part of General Motors’ finance leadership rotation program and served as the Managing Director and Treasurer at its Korea division as his last role. He received an MBA from the MIT Sloan School of Management, a Master of Science from both the Massachusetts Institute of Technology (MIT) and The Ohio State University, and a Bachelor of Technology from the Indian Institute of Technology.
Read More +Read Less -Soojin Kim, Ph.D. joined Inozyme as Senior Vice President and Chief Technical Operations Officer in March 2022. She joins Inozyme with more than 25 years of experience in pharmaceutical research and development (R&D) and manufacturing, along with an extensive background as a leader in developing expert technology groups and project teams. Prior to joining Inozyme, Dr. Kim served as senior vice president and site head of the bio plant complex at Hanmi Pharmaceutical Co.
In that role, she led the biomanufacturing and chemistry, manufacturing and controls (CMC) organization, and managed a variety of operations including, clinical/commercial manufacturing, process/analytical development, manufacturing sciences, and quality management. She previously was the senior research fellow and head of API development group, chemical development, at Boehringer Ingelheim Pharmaceuticals, and before that principal scientist and group leader in chemical process R&D at Bristol-Myers Squibb Company. Dr. Kim has published approximately 50 journal articles, book chapters, and proceedings is an inventor of more than 20 patents, and has won various awards for her work throughout her career. She holds both a Ph.D. and an M.S. in chemical engineering from the California Institute of Technology and a B.S. in chemical engineering with distinction from Cornell University.
Read More +Read Less -Kurt Gunter, M.D. joined Inozyme in June 2022. He brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations. Prior to joining Inozyme, he most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex.
Read More +Read Less -Axel Bolte is our president and chief executive officer and is a member of our board of directors since September 2015, when he co-founded our company. Since March 2017, Mr. Bolte also has served as a managing member of Healthcare Advisors GmbH, a private healthcare advisory company.
Mr. Bolte served as a venture partner at HBM Partners AG, a provider of investment advisor services in the life sciences industry, from February 2017 to September 2019 and as an investment advisor to HBM Partners AG from March 2003 to January 2017. Mr. Bolte currently serves on the board of directors of IVERIC bio, Inc. (formerly known as Ophthotech Corporation), or IVERIC, and previously served on the board of directors of Allena Pharmaceuticals, Inc., Nabriva Therapeutics plc and PTC Therapeutics, Inc., all of which are publicly traded biotechnology or pharmaceutical companies. Mr. Bolte received a degree in biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland
Read More +Read Less -Sarah Bhagat has served on our board of directors since March 2019. Dr. Bhagat has served as a partner at Sofinnova Investments, Inc., or Sofinnova, a venture capital firm, since March 2020. She served as principal at Sofinnova from January 2019 to December 2019 and as an associate from May 2017 to December 2018. Dr. Bhagat was a postdoctoral fellow at Stanford University from April 2016 to May 2017. Dr. Bhagat served as a venture fellow at Canaan Partners, a venture capital firm, from February 2015 to February 2016.
Dr. Bhagat also served as a research assistant at The Rockefeller University from May 2008 to May 2010 and a clinical research coordinator at Massachusetts General Hospital from June 2007 to May 2008. Dr. Bhagat received a B.A. in biological psychology from Franklin & Marshall College and a Ph.D. in neuroscience from Yale University.
Read More +Read Less -Reinaldo M. Diaz has served on our board of directors since January 2017. Mr. Diaz has served as venture partner at Longitude Capital Management Co., LLC, a venture capital firm focusing on healthcare companies, since November 2015. Mr. Diaz has served as the managing member and managing director of DA Advisors, LLC., a financial and strategic consulting company focusing on biopharmaceutical companies, since 2005. Mr. Diaz served as a managing director at Auven Therapeutics, a private equity firm focusing on life sciences from 2008 to 2018. Mr. Diaz served as managing member and co-founder of Diaz & Altschul Capital Management, LLC, an asset management firm focusing on healthcare companies, from 1996 to 2005.
Mr. Diaz served as managing director and head of the healthcare group at Schroder Wertheim & Co., Inc. from 1993 to 1996. Mr. Diaz served in various roles at PaineWebber Development Corporation from 1985 to 1993, including as president from 1990 to 1993. Mr. Diaz received a B.A. in general studies from Harvard University and an M.B.A. from Harvard Business School.
Read More +Read Less -Dr. Martin Edwards has served on our board of directors since September 2017. He currently also serves on the board of directors of KalVista Pharmaceuticals, Inc., Reata Pharmaceuticals Inc, and Verona Pharma plc, all publicly traded pharmaceutical companies, and he previously was on the board of directors of CoLucid Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from January 2015 to March 2017.
Dr. Edwards also served as Senior Partner at Novo Holdings A/S from 2003 to 2020. Earlier in his career, Dr. Edwards served as chief executive officer of ReNeuron Ltd., a stem cell research company based in the United Kingdom, and as global head of drug development for Novo Nordisk A/S, where he led preclinical and clinical drug development. Dr. Edwards received an MBA from the University of Warwick (UK) and his medical degree from the University of Manchester (UK).
Read More +Read Less -Rob Hopfner has served on our board of directors since November 2018. Dr. Hopfner has served as managing partner of Pivotal bioVenture Partners, a venture capital firm focused on life sciences, since October 2017. Dr. Hopfner served in various roles at Bay City Capital, a venture capital firm focused on life sciences, from August 2002 to October 2017, including as a principal from June 2007 to October 2009 and as managing director and investment partner from October 2009 to October 2017.
Dr. Hopfner received a B.S. in pharmacy from the University of Saskatchewan, an M.B.A. from the University of Chicago Booth School of Business and a Ph.D. in pharmacology from the University of Saskatchewan.
Read More +Read Less -Edward Mathers has served on our board of directors since January 2017. Mr. Mathers has served as a general partner at New Enterprise Associates, Inc., or NEA, a private venture capital firm focusing on technology and healthcare investments, since November 2019.
He served as partner at NEA from August 2008 to October 2019. Prior to joining NEA, Mr. Mathers served as executive vice president, corporate development and venture at MedImmune, Inc., or MedImmune, a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Mr. Mathers currently serves on the board of directors of ObsEva SA, Rhythm Pharmaceuticals, Inc., Synlogic, Inc. (formerly known as Mirna Therapeutics, Inc.), Trevi Therapeutics, Inc. and Mirum Pharmaceuticals, Inc., all publicly traded pharmaceutical companies, and he previously served on the board of directors of Liquidia Technologies, Inc., a publicly traded life sciences company, from April 2009 to May 2019 and Ra Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, from February 2010 to April 2020. Mr. Mathers received a B.S. in chemistry from North Carolina State University.
Read More +Read Less -Lynne Sullivan has served on our board of directors since May 2020. Ms. Sullivan expects to join UNITY Biotechnology, Inc., a biotechnology company, as the interim chief financial officer in August 2020. Ms. Sullivan served as chief financial officer of Compass Therapeutics, LLC, a biotechnology company, from December 2018 to August 2019.
Ms. Sullivan served in various roles at Biogen Inc., a biotechnology company, including vice president of tax from April 2008 to February 2015, vice president of tax and corporate finance from February 2015 to March 2016 and senior vice president of finance from March 2016 to December 2018. Ms. Sullivan currently serves on the board of directors of Solid Biosciences Inc., a publicly traded biotechnology company, resTORbio, Inc., a publicly traded biopharmaceutical company, and BiomX Inc., a publicly traded biopharmaceutical company. Ms. Sullivan was a certified public accountant for over 20 years.
Read More +Read Less -Douglas Treco, Ph.D., has served as the chairman of our board of directors since May 2020. Dr. Treco co-founded RA Pharmaceuticals, Inc., or RA Pharma, a pharmaceutical company, in 2008, which was acquired by UCB S.A. in April 2020. He has served as the president and chief executive officer of Ra Pharma since June 2008.
Dr. Treco served as an entrepreneur-in-residence with Morgenthaler Ventures, a venture capital firm, from January 2008 to May 2014. Dr. Treco served as a visiting scientist in the Department of Molecular Biology at Massachusetts General Hospital and as a lecturer in genetics at Harvard Medical School from 2004 to 2007. Dr. Treco currently serves on the board of directors of CRISPR Therapeutics AG and served on the board of directors of Ra Pharma from June 2008 to April 2020. Dr. Treco received a B.A. in Biology from the University of Delaware and a Ph.D. in biochemistry and molecular biology from the State University of New York, Stony Brook, and performed post-doctoral research at the Salk Institute for Biological Studies and Massachusetts General Hospital.
Read More +Read Less -
Inozyme Pharma, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Inozyme Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Inozyme Pharma, Inc. or its management. Inozyme Pharma, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
.svg)
